CD33
| Official symbol: | CD33 |
| Full name: | CD33 molecule |
| Location: | 19q13.41 |
| Also known as: | SIGLEC3, SIGLEC-3, FLJ00391, p67 |
| Entrez ID: | 945 |
| Ensembl ID: | ENSG00000105383 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
| Expression restricted in 1 cancer type(s) | |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.00 | | Gscore (Del): | 0.00 |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | NA |
|
|
|
| |
|
|
|
| Functional class: | Not specified |
| JensenLab PubMed score: | 774.44 (Percentile rank: 93.93%) |
| PubTator score: | 888.12 (Percentile rank: 96.00%) |
| Target development/druggability level: | TclinThese targets have activities in DrugCentral (ie. approved drugs) with known mechanism of action. |
| Tractability (small molecule): | Discovery PrecedenceTargets with ligands; Targets with crystal structures with ligands |
| Tractability (antibody): | Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets |
